Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxepin low dose - Somaxon Pharmaceuticals

Drug Profile

Doxepin low dose - Somaxon Pharmaceuticals

Alternative Names: Doxepin low dose; Silenor; SO-101

Latest Information Update: 09 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Somaxon Pharmaceuticals
  • Developer Endo International; Somaxon Pharmaceuticals
  • Class Antipruritics; Dibenzoxepins; Oxepins; Sleep disorder therapies; Small molecules; Tricyclic antidepressants
  • Mechanism of Action Histamine H1 receptor antagonists; Neurotransmitter uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Insomnia

Most Recent Events

  • 30 Apr 2019 Currax Pharmaceuticals acquired all the assets of Pernix Therapeutics ,
  • 28 Mar 2017 Pernix Therapeutics has patents and pending patent applications for doxepin low-dose in USA
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top